Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics

References

• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185.
   PubMed Web of Science ®Google Scholar
• Mullard A. New drugs cost US$2.6 billion to develop. Nat Rev Drug Discov. 2014;13:877.
   Web of Science ®Google Scholar
• Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov. 2004;3:417–429.
   PubMed Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Feldman L, Seckler A, et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272–277.
   PubMed Web of Science ®Google Scholar
• Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87:356–361.
   PubMed Web of Science ®Google Scholar
• Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14:475–486.
   PubMed Web of Science ®Google Scholar
• Jadhav PR, Cook J, Sinha V, et al. A proposal for scientific framework enabling specific population drug dosing recommendations. J Clin Pharmacol. 2015;55:1073–1078.
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Harvey RD, Damiette Smit MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol. 2017;35:3753–3759.
   PubMed Web of Science ®Google Scholar
• Bourgeois FT, Murthy S, Pinto C, et al. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012;130:285–292.
   PubMed Web of Science ®Google Scholar
• Cella M, Knibbe C, Danhof M, et al. What is the right dose for children? Br J Clin Pharmacol. 2010;70:597–603.
   PubMed Web of Science ®Google Scholar
• Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999;88:965–968.
   PubMed Web of Science ®Google Scholar
• Darwich AS, Ogungbenro K, Vinks AA, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101:646–656.
   PubMed Web of Science ®Google Scholar
• Verma M. Personalized medicine and cancer. J Pers Med. 2012;2:1–14.
   PubMedGoogle Scholar
• Day S, Coombes RC, McGrath-Lone Let al,. Stratified, precision or personalised medicine? Cancer services in the ‘real world’ of a London hospital. Sociol Health Illn. 2017;39:143–158.
   PubMed Web of Science ®Google Scholar
• NHS England, Care quality commission, Health education England, monitor, public health England TDA. Five year forward view. 2014.
   Google Scholar
• The White House. Precision medicine initiative: Privacy and trust principles. 2015; 1–4.
   Google Scholar
• European Medicines Agency. EMA/199678/2016 - Reflection paper on extrapolation of efficacy and safety in paediatric medicine development (Draft). 2016.
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration. General clinical pharmacology considerations for pediatric studies for drugs and biological products guidance for industry - draft guidance. 2014;1–25.
   Google Scholar
• Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92:50–61. .
   PubMed Web of Science ®Google Scholar
• Younis IR, Robert Powell J, Rostami-Hodjegan A, et al. Utility of model-based approaches for informing dosing recommendations in specific populations: report from the public AAPS workshop. J Clin Pharmacol. 2017;57:105–109.
   PubMed Web of Science ®Google Scholar
• Shebley M. Physiologically-based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104:88-110.
   Google Scholar
• Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 2014;53:327–346.
   PubMed Web of Science ®Google Scholar
• Fernandez E, Perez R, Hernandez A, et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3:53–72.
   PubMedGoogle Scholar
• Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19:262–276.
   PubMedGoogle Scholar
• Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79:395–404.
   PubMed Web of Science ®Google Scholar
• Wan H, Goodkind D, Kowal P. An aging world: 2015. U.S. Census Bureau, International population reports. Washington (DC): U.S. Government Publishing Office; 2016;P95/I16-1.
   Google Scholar
• Burris JF, Tortorici MA, Mandic M, et al. Dosage adjustments related to young or old Age and organ impairment. J Clin Pharmacol. 2016;56:1461–1473.
   PubMed Web of Science ®Google Scholar
• Chetty M, Johnson TN, Polak S, et al. Physiologically based pharmacokinetic modelling to guide drug delivery in older people. Adv Drug Deliv Rev. 2018 [cited Oct 2018];[12 p.]. DOI: 10.1016/j.addr.2018.08.013
   PubMed Web of Science ®Google Scholar
• Johnston C, Kirkpatrick CM, McLachlan AJ, et al. Physiologically based pharmacokinetic modeling at the extremes of age. Clin Pharmacol Ther. 2013;93:148.
   PubMed Web of Science ®Google Scholar
• Ke AB, Nallani SC, Zhao P, et al. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol. 2014;77:554–570.
   PubMed Web of Science ®Google Scholar
• Ghiculesco RA. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescr. 2008;31:42–44.
   Web of Science ®Google Scholar
• Kang J-S, Lee M-H. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1–10.
   PubMedGoogle Scholar
• Gonzalez D, Rao GG, Bailey SC, et al. Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci. 2017;10:443–454.
   PubMed Web of Science ®Google Scholar
• Momper JD, Burckart GJ, Jadhav P. Applications of population pharmacokinetics for pediatric drug development. Pediatr Drug Dev. Chichester, UK: John Wiley & Sons Ltd.; 2013. p. 306–315.
   Google Scholar
• Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38:1702–1706.
   PubMed Web of Science ®Google Scholar
• Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. Aaps J. 2012;14:119–132. .
   PubMed Web of Science ®Google Scholar
• Charles B. Population pharmacokinetics: an overview. Aust Prescr. 2014;37:210–213.
   Google Scholar
• Manolis E, Pons G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol. 2009;68:493–501.
   PubMed Web of Science ®Google Scholar
• Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT pharmacometrics Syst Pharmacol. 2013;2:e63.
   PubMedGoogle Scholar
• Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol. 2016;5:516–531.
   PubMedGoogle Scholar
• Leong R, Vieira MLT, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91:926–931.
   PubMed Web of Science ®Google Scholar
• Fura A. Role of pharmacologically active metabolites in drug discovery and development. Drug Discov Today. 2006;11:133–142.
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Tibboel D, Leeder JS. Drug metabolism for the paediatrician. Arch Dis Child. 2014;99:1137–1142. .
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol. 2001;41:1149–1179.
   PubMed Web of Science ®Google Scholar
• Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011;12:487–497.
   PubMed Web of Science ®Google Scholar
• Martin SJ, Garvin CG, McBurney CR, et al. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2001;47:581–587.
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485–505.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Yang L-P, Zhou Z-W, et al. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. Aaps J. 2009;11:481–494.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development. Med Res Rev. 2001;21:397–411.
   PubMed Web of Science ®Google Scholar
• Lapple F, von Richter O, Fromm MF, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003;13:565–575.
   PubMedGoogle Scholar
• Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118:250–267.
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VEet al,. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30:883-891.
   Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–391.
   PubMed Web of Science ®Google Scholar
• Blake MJ, Castro L, Leeder JS, et al. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med. 2005;10:123–138.
   PubMed Web of Science ®Google Scholar
• Langenfeld E, Zanger UM, Jung K, et al. Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics. 2009;9:2313–2323.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Potter PM, Hutzler JM, et al. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. Aaps J. 2016;18:1391–1405.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang YD, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. Aaps J. 2009;11:300–306.
   PubMed Web of Science ®Google Scholar
• International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–236.
   PubMed Web of Science ®Google Scholar
• Döring B, Petzinger E. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev. 2014;46:261–282.
   PubMed Web of Science ®Google Scholar
• König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65:944–966.
   PubMed Web of Science ®Google Scholar
• Staudinger JL. Disease, drug metabolism, and transporter interactions. Pharm Res. 2013;30:2171–2173.
   PubMed Web of Science ®Google Scholar
• Joyce H, McCann A, Clynes M, et al. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol. 2015;11:795–809.
   PubMed Web of Science ®Google Scholar
• Ma Q, Lu AYH. Pharmacogenetics, Pharmacogenomics, and individualized medicine. Sibley DR, editor. Pharmacol Rev. 2011;63:LP–459.
   Web of Science ®Google Scholar
• English BA, Dortch M, Ereshefsky L, et al. Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012;14:376–390.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Swen JJ, Thorn CF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93:402–408.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102:688–700.
   PubMed Web of Science ®Google Scholar
• Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol Baishideng Publishing Group Inc. 2016;22:1260–1278.
   PubMed Web of Science ®Google Scholar
• Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931–956.
   PubMed Web of Science ®Google Scholar
• Calvier EAM, Krekels EHJ, Yu H, et al. Drugs being eliminated via the same pathway will not always require similar pediatric dose adjustments. CPT Pharmacometrics Syst Pharmacol. 2018;7:175–185.
   PubMedGoogle Scholar
• Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol. 2000;106:S128–S138.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochrome P450s and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2011;40:83–92.
   PubMed Web of Science ®Google Scholar
• Feteisi H A, Achour B, Rostami-Hodjegan A, et al. Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics for in vitro – in vivo extrapolation of drug metabolism and transport and considerations in selecting appropriate techniques. Expert Opin Drug Metablism Toxicol. 2015;11:1357–1369.
   PubMed Web of Science ®Google Scholar
• Al-Majdoub ZM, Carroll KM, Gaskell SJ, et al. Quantification of the proteins of the bacterial ribosome using QconCAT technology. J Proteome Res. 2014;13:1211–1222.
   PubMed Web of Science ®Google Scholar
• Achour B, Al-Majdoub ZM, Al Feteisi H, et al. Ten years of QconCATs: application of multiplexed quantification to small medically relevant proteomes. Int J Mass Spectrom. 2015;391:93–104.
   Web of Science ®Google Scholar
• Russell MR, Achour B, McKenzie EA, et al. Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. J Proteome Res. 2013;12:5934–5942.
   PubMed Web of Science ®Google Scholar
• Achour B, Russell MMR, Barber J, et al. Simultaneous quantification of the abundance of several cytochrome p450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes. Drug Metab. 2014;42:500–510.
   Google Scholar
• Stevens J, Marsh S, Zaya M, et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos. 2008;36:1587–1593.
   PubMed Web of Science ®Google Scholar
• Johnsrud EK, Koukouritaki SB, Divakaran K, et al. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther. 2003;307:402-407.
   Web of Science ®Google Scholar
• Divakaran K, Hines RN, McCarver DG. Human hepatic UGT2B15 developmental expression. Toxicological Sci. 2014;141:292–299.
   PubMed Web of Science ®Google Scholar
• Miyagi SJ, Milne AM, Coughtrie MWH, et al. Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. Drug Metab Dispos. 2012;40:1321–1327.
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50:259–265.
   PubMed Web of Science ®Google Scholar
• Zaya MJ, Hines RN, Stevens JC. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006;34:2097–2101.
   PubMed Web of Science ®Google Scholar
• Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem. 1998;251:893–898.
   PubMedGoogle Scholar
• De Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999;36:439–452.
   PubMed Web of Science ®Google Scholar
• Prasad B, Gaedigk A, Vrana M, et al. Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics. Clin Pharmacol Ther. 2016;100:362–370.
   PubMed Web of Science ®Google Scholar
• Prasad B, Evers R, Gupta A, et al. Interindividual variability in hepatic Oatps and P-glycoprotein (ABCB1) protein expression: quantification by LC-MS/MS and influence of genotype, age and sex. Drug Metab Dispos. 2013;42:78–88.
   PubMed Web of Science ®Google Scholar
• Elmorsi Y, Barber J, Rostami-Hodjegan A. Ontogeny of hepatic drug transporters and relevance to drugs used in paediatrics. Drug Metab Dispos. 2015;44:992–998.
   PubMed Web of Science ®Google Scholar
• Brouwer KLR, Aleksunes LM, Brandys B, et al. Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther. 2015;98:n/a-n/a.
   PubMed Web of Science ®Google Scholar
• Pinto RB, Schneider ACR, Da Silveira TR. Cirrhosis in children and adolescents: an overview. World J Hepatol. 2015;7:392–405.
   PubMed Web of Science ®Google Scholar
• Spada M, Riva S, Maggiore G, et al. Pediatric liver transplantation. World J Gastroenterol. 2009;15:648674.
   Web of Science ®Google Scholar
• Yoon PW, Bresee JS, Olney RS, et al. Epidemiology of biliary atresia: a population-based study. Pediatrics. 1997;99:376–382.
   PubMed Web of Science ®Google Scholar
• Della Corte C, Vajro P, Socha P, et al. Pediatric non-alcoholic fatty liver disease: recent advances. Clin Res Hepatol Gastroenterol. 2014;38:419–422.
   PubMed Web of Science ®Google Scholar
• Mack CL, Feldman AG, Sokol RJ. Clues to the etiology of bile duct injury in Biliary atresia. Semin Liver Dis. 2012;32:307–316.
   PubMed Web of Science ®Google Scholar
• McKiernan PJ, Baker AJ, Kelly DA. The frequency and outcome of biliary atresia in the UK and Ireland. including commentary by Rothwell PM. Lancet. 2000;355:25–30.
   PubMed Web of Science ®Google Scholar
• Nio M, Wada M, Sasaki H, et al. Effects of age at Kasai portoenterostomy on the surgical outcome: a review of the literature. Surg Today. 2015;45:813–818.
   PubMed Web of Science ®Google Scholar
• Feldman AG, Mack CL. Biliary atresia: clinical lessons learned. J Pediatr Gastroenterol Nutr. 2015;61:167–175.
   PubMed Web of Science ®Google Scholar
• Upreti VV, Wahlstrom JL. Meta analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56:266–283.
   PubMed Web of Science ®Google Scholar
• Canet MJ, Cherrington NJ. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Expert Opin Drug Metab Toxicol. 2014;10:1–11.
   PubMed Web of Science ®Google Scholar
• Dzierlenga AL, Clarke JD, Hargraves TL, et al. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2015;352:462–470.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao K-N CC. The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. Ann Transl Med. 2014;2:7.
   PubMedGoogle Scholar
• George J, Liddle C, Murray M, et al. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol. 1994;49:873–881.
   Web of Science ®Google Scholar
• Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006;26:1175–1186.
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20:2515–2532.
   PubMed Web of Science ®Google Scholar
• Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
   PubMed Web of Science ®Google Scholar
• Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450 – mediated drug metabolism and pharmacokinetics. Nature. 2009;85:434–438.
   Google Scholar
• Nakai K, Tanaka H, Hanada K, et al. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chron. Drug Metab Dispos. 2008;36:1786–1793.
   PubMed Web of Science ®Google Scholar
• Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab. 2012;13:1327–1344.
   PubMed Web of Science ®Google Scholar
• Debinski HS, Lee CS, Danks JA, et al. Localization of uridine 5ʹ-diphosphate- glucuronosyltransferase in human liver injury. Gastroenterology. 1995;108:1464–1469.
   PubMed Web of Science ®Google Scholar
• Furlan V, Demirdjian S, Bourdon O, et al. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther. 1999;289:1169–1175.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - A practical guide. Aliment Pharmacol Ther. 2013;37:1132–1156.
   PubMed Web of Science ®Google Scholar
• Wilkening S, Bader A. Differential regulation of CYP3A4 and CYP3A7 by dimethylsulfoxide in primary human hepatocytes. Basic Clin Pharmacol Toxicol. 2004;95:92–93.
   PubMed Web of Science ®Google Scholar
• Grimsrud KN, Sherwin CMT, Constance JE, et al. Special population considerations and regulatory affairs for clinical research. Clin Res Regul Aff. 2015;32:47–56.
   PubMedGoogle Scholar
• Ke AB, Rostami-Hodjegan A, Zhao P, et al. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol. 2014;54:53–69.
   PubMed Web of Science ®Google Scholar
• Masters JC, Wiernik PH. Are we ready to include organ-impaired patients in oncology trials? A clinical pharmacology perspective on recent recommendations. J Clin Pharmacol. 2018: 1–3.
   Web of Science ®Google Scholar
• Prasad B, Gaedigk A, Vrana M, et al. Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics. Clin Pharmacol Ther. 2016;100:362–370.
   PubMed Web of Science ®Google Scholar